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Retinitis pigmentosa (RP) is the most frequent form of inherited retinal dystrophy. RP is genetically heterogeneous and the genes
identified to date encode proteins involved in a wide range of functional pathways, including photoreceptor development, pho-
totransduction, the retinoid cycle, cilia, and outer segment development. Here we report the identification of biallelic mutations
in Receptor Expression Enhancer Protein 6 (REEP6) in seven individuals with autosomal-recessive RP from five unrelated families.
REEP6 is a member of the REEP/Yop1 family of proteins that influence the structure of the endoplasmic reticulum but is
relatively unstudied. The six variants identified include three frameshift variants, two missense variants, and a genomic rear-
rangement that disrupts exon 1. Human 3D organoid optic cups were used to investigate REEP6 expression and confirmed
the expression of a retina-specific isoform REEP6.1, which is specifically affected by one of the frameshift mutations. Expression
of the two missense variants (c.383C>T [p.Pro128Leu] and c.404T>C [p.Leu135Pro]) and the REEP6.1 frameshift mutant in
cultured cells suggest that these changes destabilize the protein. Furthermore, CRISPR-Cas9-mediated gene editing was used to
produce Reep6 knock-in mice with the p.Leu135Pro RP-associated variant identified in one RP-affected individual. The homozy-
gous knock-in mice mimic the clinical phenotypes of RP, including progressive photoreceptor degeneration and dysfunction
of the rod photoreceptors. Therefore, our study implicates REEP6 in retinal homeostasis and highlights a pathway previously
uncharacterized in retinal dystrophy.Introduction
Retinitis pigmentosa (RP [MIM: 268000]) is the most com-
mon inherited retinal dystrophy, affecting approximately
1 in 4,000 individuals1 and resulting in more than 1
million visually impaired individuals worldwide. RP is
genetically heterogeneous with autosomal-dominant,
autosomal-recessive, and X-linked modes of inheritance
and at least 58 genes associated with an autosomal-reces-
sive form (arRP; RetNet). These genes encode proteins
involved in a diverse range of functional pathways in the
neural retina including photoreceptor development, pho-
totransduction, retinoid cycle, cilia, and outer segment
development and protein transport.2,3 Mutations in any
one of these many pathways leads to a remarkably similar
phenotype characterized by rod photoreceptor dysfunc-
tion and degeneration and subsequent cone degenera-
tion.4,5 Affected individuals commonly present with
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involved. Despite the development of targeted next-gener-
ation sequencing screening strategies for identifying
pathogenic variants in genes already associated with RP,
an estimated 40% of cases remain without a molecular
diagnosis,6 suggesting that mutations may exist in genes
not previously associated with Mendelian disease.
Here we report the identification of biallelic mutations
in Receptor Expression Enhancer Protein 6 (REEP6 [MIM:
609346]) in individuals with arRP from five unrelated
families. REEP6 encodes a putative endoplasmic reticulum
(ER) shaping factor, which is highly expressed in rod
photoreceptor cells. All six alleles we have identified are
predicted to be loss-of-function variants, including one
allele that disrupts the rod photoreceptor-specific isoform
REEP6.1. A knock-in mouse model of one of the identified
missense variants leads to retinal degeneration and con-
firms that REEP6 function is important for retinal
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Material and Methods
Clinical Methods
The study protocol adhered to the tenets of the Declaration of
Helsinki and received approval from the appropriate local ethics
committees. Written, informed consent was obtained from all
participants or parents of children prior to their inclusion in
this study. Individual A-II:1 was diagnosed in the United States
and referred by eyeGENE-approved certified eye specialists and
informed consent was obtained. Clinical data and family history
were obtained by contacting the referring clinician to the eyeGENE
database. For the UK cohort, DNA from six affected individuals
from four families (familiesB,C,D, E)were available for genotyping
and four of these individuals underwent detailed clinical examina-
tion and retinal imaging, including 35-degree color fundus photo-
graphy (Topcon Great Britain), ultra-widefield confocal scanning
laser imaging with Optos (Optos plc), or Spectralis (Spectralis,
Heidelberg Engineering) fundus autofluorescence (FAF) imaging
and Spectralis optical coherence tomography (OCT).Whole-Exome Sequencing
Individual A-II:1 underwent retinal capture sequencing (RCS)
and whole-exome sequencing (WES) at the Human Genome
Sequencing Center, Baylor College of Medicine. In brief, about
1 mg of peripheral blood mononuclear cell (PBMC)-derived
genomic DNA was processed for RCS to screen for variants in
known disease-causing genes as described previously.7 For WES,
the NimbleGenSeqCap EZ Hybridization and Wash kit (Nimble-
genSeqCap EZ Human Exome Library v.2.0) was used according
to the manufacturer’s protocols. Sequencing of captured libraries
was performed on Illumina HiSeq 2000 (Illumina) as 100 bp
paired-end reads according to the manufacturer’s protocol.
Reads were mapped to hg19 human reference sequence (build
GRCh37) using Burrows-Wheeler Aligner.8 Base quality recalibra-
tion, local realignment, and variant calling were performed as
previously described.7 Variant frequencies were obtained from a
series of public and internal control databases7 as well as the
Exome Aggregation Consortium (ExAC) database. Since RP is a
Mendelian disorder, variants with a minor allele frequency
(MAF) higher than 0.005 (for a recessive model) or 0.0001 (for
a dominant model) were filtered out. After frequency-based
filtering, synonymous variants were filtered out and the patho-
genicity of the remaining variants were predicted using SIFT,9
PolyPhen-2,10 LRT,11 MutationTaster,12 and MutationAssessor13
as previously described.7 Genes with biallelic variants were con-
sidered, assuming autosomal-recessive inheritance (Table S1).
Variants were ranked based on their pathogenicity score and bio-
logical plausibility.
Individual B-II:8 underwent WES as part of a large collaborative
study on rare inherited retinal dystrophy (UK Inherited Retinal
Dystrophy Consortium) at the University of Leeds Next Genera-
tion Sequencing Facility, UK. In brief, 200 ng of PBMC-derived
genomic DNA was processed according to the Agilent SureSelect
XT Library Prep protocol (Agilent Technologies) with exons being
captured using the SureSelect Exome V5 Capture library. After
hybridization and indexing, six samples were pooled and 100 bp
paired end sequencing was performed (Illumina HiSeq 2500
sequencer). Reads were aligned to the hg19 human reference
sequence (build GRCh37) using Novoalign v.2.08. Duplicate
reads were marked with Picard tools MarkDuplicates. Calling was
performed using GATK, creating gVCF formatted files for each1306 The American Journal of Human Genetics 99, 1305–1315, Decesample. The individual gVCF files for the individual discussed in
this study, in combination with ~4,500 clinical exomes (UCL-
exomes consortium), were combined into merged VCF files for
each chromosome containing on average 100 samples each. The
final variant calling was performed using the GATK Genotype
gVCFs module jointly for all samples (cases and controls). Variant
quality scores were then re-calibrated according to GATK best
practices separately for indels and SNVs. Resulting variants were
annotated using ANNOVAR based on Ensembl gene and transcript
definitions. Candidate variants were filtered based on function
(non-synonymous, presumed loss-of-function, or splicing) and
MAF (<0.005) in an in-house exome-sequencing control dataset
of approximately 1,000 individuals (UCLEx), NHLBI GO Exome
Sequencing Project (EVS), and 1000 Genomes phase 1 dataset, re-
sulting in 549 rare variants. Based on family consanguinity, 36
homozygous variants (Table S2) were further manually interro-
gated for variant call quality, predicted pathogenicity, and biolo-
gical plausibility.
Whole-Genome Sequencing
DNA from 599 unrelated affected individuals with inherited
retinal disease, ascertained from the Inherited Eye Disease clinics
at Moorfields Eye Hospital (MEH), London, underwent whole-
genome sequencing (WGS) as part of the National Institute of
Health Research (NIHR) BioResource – Rare Diseases project. In
brief, PBMC-derived genomic DNA was processed using the
Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina)
and sequenced using an Illumina Hiseq 2500, generating mini-
mum coverage of 153 for ~95% of the genome. Reads were aligned
to hg19 human reference sequence (build GRCh37) using Isaac
aligner (Illumina). SNVs and indels were identified using Isaac
variant caller. Variant examination was performed only on the
SNVs and indels that met the following criteria: passed standard
quality filters, predicted to alter the sequence of a protein, and
had an MAF <0.01 in the 1000 Genomes database, EVS, the
UK10K database, and ExAC and <0.02 in ~6,000 internal control
genomes. In the first instance, likely disease-causing variants in
a panel of 192 genes previously associated with inherited retinal
disease were interrogated (gene list available on request).
Sanger Sequencing
In order to confirm the REEP6 variants identified by next-genera-
tion sequencing, bi-directional direct Sanger sequencing was per-
formed using specific oligonucleotide primers flanking the exons.
Family segregation was performed in all available family members
(Figure 1). 400 RP probands without a molecular diagnosis were
screened for mutations in REEP6 by bi-directional direct Sanger
sequencing of all coding exons and intron/exon boundaries
(primers and conditions available on request).
Human iPSC Photoreceptor Differentiation and
Analyses
Control iPSCs were generated by reprogramming fibroblasts as
described previously.14 iPSCs were maintained on geltrex in
mTESR-E8 media (Stem Cell Technologies). Directed differentia-
tion of iPSCs into three-dimensional optic cups was based on
the protocol by Nakano et al.15 In brief, embryoid bodies (EBs)
were generated in V-bottomed 96-well plates and differentiated
for 18 days prior to transfer to non-adherent dishes. Pouches of
transparent neuroepithelium were manually isolated from EBs
under a dissecting microscope at day 30 and transferred to freshmber 1, 2016
Figure 1. Autosomal-Recessive RP Families and Associated REEP6 Variants
(A) Pedigrees of all families with RP in this study (families A to E). Proband II.1 from family A is compound heterozygous for REEP6
variants (M1/M2). All other affected individuals were homozygous for the respective REEP6 variants indicated (M3, M4, M5, M6). M3
c.5835_115þ936delinsAC027307.5:79083_79240inv is abbreviated to c.5835_115þ936delins.
(B) REEP6 gene structure with nucleotide positions for M1 toM6mapped on to exons (E1–E6). Exon 5 is present only in isoform REEP6.1
(absent from REEP6.2). Protein structure of REEP6.1 and REEP6.2 with position of the corresponding mutations indicated.
(C) Sequence reads from individual A-II:1 aligned against þ strand of hg19 showing heterozygous mutations in REEP6. Both mutations
are in exon 4: c.T404C (p.Ala150Profs*2) and c.448delG (p.Leu135Pro) are in trans.non-adherent dishes. These were maintained for up to 21 weeks.
Optic cups were selected after morphological assessment under a
light microscope at several time points during the differentiation
and fixed in 4% paraformaldehyde (PFA) for 40 min at 4C, cryo-
protected by incubation overnight in 30% sucrose in phosphate
buffer saline (PBS), embedded in OCTcompound (Sakura Finetek),
frozen, and cryosectioned (6 mm sections). Cryosectioned optic
cups were incubated in blocking buffer (10% normal goat serum
[NGS], 0.1% Triton X-100 in PBS) for 1 hr at room temperature
before incubation with primary antibodies (mouse anti-rhodopsin
4D2 [1:500; Millipore], rabbit anti-REEP6 [1:100; Proteintech cat#
120889-1-AP], mouse anti-cone-arrestin clone 7G6 [1:100; kind
gift of Peter MacLeish, Morehouse School of Medicine, Atlanta,
GA, USA]) for 2 hr at room temperature. Species-specific anti-IgG
Alexa Fluor 488 or 594 secondary antibodies were used as appro-
priate. Nuclei were visualized using DAPI (2 mg/mL) staining
for all images. RNA was extracted and synthesis of cDNA wasThe American Jouperformed using Tetro cDNA synthesis kit (Bioline) for reverse
transcription. GoTaq Green (Promega) was used for amplification
by PCRwith using standard protocols and conditions with primers
REEP6 F: 50-TCCTGTCCTGGTTCCCTTTC-30 and REEP6 R: 50-GGC
TGCTTCACTTGTCCTTC-30.REEP6 Expression Constructs and Transient
Transfection
The REEP6 splice variant open reading frames were amplified
from control D124 optic cup cDNA16 using the primers REEP6_F1,
50-GCTAGCCACCATGGACGGCCTGAGGCAGCGCGTGGAG-30,
and REEP6_R1stop, 50-AATCTAGAGCGGCCGCTCACTTGTCCTT
CGGCTGCGGGGTCTGGC-30. The two observed PCR ampli-
cons corresponded to the predicted REEP6.1 and REEP6.2
sizes and were excised and gel purified (QIAquick Gel Extraction
Kit, QIAGEN) prior to cloning into the pSC-B-amp/kan vectorrnal of Human Genetics 99, 1305–1315, December 1, 2016 1307
(StrataClone Blunt PCR Cloning Kit, Agilent Technologies).
Clone identities (REEP6.1, GenBank: NM_001329556.1; REEP6.2,
GenBank: NM_138393.2) were confirmed by Sanger sequencing
(Source BioScience). Mutations were introduced by site-di-
rected mutagenesis (Q5 Site-Directed Mutagenesis Kit, New
England Biolabs) using primers and conditions specified by the
NEBaseChanger software. Sequence integrity was confirmed by
Sanger sequencing as before. To create expression vectors, wild-
type (WT) and mutant REEP6.1 sequences were cloned into
pEYFP-N1 (Clontech) digested with BmtI and NotI to release the
EYFP sequence. WT and mutant REEP6.1 expression plasmids
were transfected into SK-N-SH (ATCC) cells using TransIT-LT1
Transfection Reagent (Mirus Bio) using the manufacturers’ recom-
mended conditions, in 8-well Nunc Lab-Tek Permanox chamber
slides (ThermoFisher Scientific) plated at 40,000 cells/well and
6-well plates plated at 500,000 cells/well.
Immunocytochemistry
At 20 hr after transfection, SK-N-SH neuroblastoma cells in 8-well
chamber slides were treated for 2 hr with 50 mM MG-132 (in
DMSO) or the vehicle DMSO. Standard protocols were used for
immunocytochemistry. In brief, transfected SK-N-SH cells in
chamber slides were washed with PBS and fixed for 15 min with
4% formaldehyde (in PBS) and permeabilized with 0.1% Triton
X-100 (in PBS) for 5 min, and non-specific antibody binding
was blocked for 1 hr using 3% BSA and 10% secondary antibody
species serum in PBS. Primary antibodies, rabbit anti-REEP6
(1:200; Proteintech) and mouse anti-KDEL (1:200; Enzo Life
Sciences cat# ADI-SPA-827-F), were applied for 1 hr in the blocking
solution. Appropriate Alexa Fluor 488 and 594 secondary
antibodies were incubated for 45 min in the blocking solution.
Nuclei were labeled with DAPI (in PBS) and coverslips mounted
with Fluorescence Mounting Medium (Dako). Cells were imaged
on an Zeiss LSM 700 Confocal Microscope. Digital processing
was undertaken with ImageJ and figures prepared in Graphic
(Autodesk).
Cycloheximide Treatment
At 20 hr after transfection, SK-N-SH cells in 6-well plates were
treated with 50 mM cycloheximide. Cells were harvested at
T ¼ 0, þ2, and þ4 hr cycloheximide exposure time points. Cells
were washed twice with PBS and collected in 300 mL RIPA buffer
before brief sonication. 53 sample buffer was added to aliquots
prior to thermal denaturation and prior to resolution by SDS-
PAGE (15%) and western blotting. Western blots were blocked in
5% Marvel (in PBS) prior to incubation with rabbit anti-REEP6
(1:2,000; Proteintech) and mouse anti-b-tubulin (1:3,000; Sigma-
Aldrich, cat# T4026). Horseradish peroxidase (HRP)-conjugated
secondary antibodies (1:30,000) were visualized with Pierce ECL
2 Substrate (ThermoScientific). Western blots were visualized on
a Bio-Rad ChemiDoc MP Imaging System and quantitated using
Image Lab 5.2.1 (Bio-Rad Laboratories). Statistical significances
were calculated by Student’s t test.
Generation of Reep6 Knock-in Mice using CRISPR
Targeting
Reep6L135P/ L135P mice harboring the c.404T>C mutation identi-
fied in individual A-II:1 were generated using the CRISPR-Cas9
gene-targeting approach. All animal operations were approved
by the Institutional Animal Care and Use Committee at Baylor
College of Medicine. Single-guide RNA (sgRNA) target site for1308 The American Journal of Human Genetics 99, 1305–1315, Decemurine Reep6 close to the disease variant in exon 4 was selected
using CRISPR design tool (50-AGAGTGGTCTTATGACGCGATGG-
30). Additionally, the donor template contained a silent mutation
(c.408C>T) to avoid sgRNA recognition and excision. The murine
Reep6 sgRNA was cloned into pDR274, a cloning vector (Addgene)
to form a T7 promoter-mediated sgRNA expression vector. BsaI
digestion was performed to linearize the vector. After gel purifica-
tion (QIAGEN), we used the linearized expression vector as a
template to produce sgRNA using the Maxiscript T7 kit (Life Tech-
nologies) and purified with RNA Clean and Concentrator-25
(Zymo Research). RNA concentration was measured using a
NanoDrop ND1000. Single-stranded donor oligonucleotides
(ssODN) spanning the region were designed and contained the
disease variant and an extra mutation at the PAM site to avoid
degradation of the donor by Cas9. ssODN was ordered from IDT
as an ultramer (50-CTTCCTGTTATTTTGCATGACGCCCGGACC
CTGGAACGGGGCATTACTACCATATCATCGCGTCATAAGACCA
CTCTTTCTAAAGCACCACATGGCTCTAGACAGCGCCGCGAGC
CAGCT-30). To make cas9 mRNA, a modified pX33017 was
linearized with NotI and used as template for RNA production
(mMESSAGE mMACHINE T7 Transcription Kit, Invitrogen).
For microinjections, the donor oligos (33 ng/mL) were mixed
with Cas mRNA (40 ng/mL) and sgRNA (20 ng/mL) and microin-
jected into C57BL/6 embryos at the single-cell stage. Once the
embryos reached blastocyst stage, they were transferred into the
uterus of pseudopregnant females to obtain founder mice. To
genotype the subsequent generations and onward of Reep6
knock-in mice, we used a genomic PCR assay using the following
primers: Reep6_KI_F: 50-TCCTGTTCTGGTTCCCTTTCTA-30 and
Reep6_KI_M13R: 50-CTGCTCAGGAAACAGCTATGACGGAAAAAT
AAATCCAGCATCCA-30. All mice in this study were maintained
under light cycles of 12-hr light and 12-hr dark.Electroretinography
Mice were dark-adapted overnight, then anesthetized with keta-
mine (22 cmg/kg), xylazine (4.4 cmg/kg), and acepromazine
(0.37 cmg/kg) by intraperitoneal injection. Pupils were dilated in
dim red light with tropicamide (1.0%) and phenylephrine
(2.5%) solutions and the cornea anesthetized with proparacaine
(1.0%). Goniosoft (2.5%) was generously applied on the cornea
to keep it moistened and enhance contact between the cornea
and the ERG electrode. Scotopic ERGwas performed at six flash in-
tensities,24,14, 4, 0, and 10 dB (0.01, 0.1, 1, 2.5, 25 cd*s/m2)
on 4- to 6-month-old Reep6L135P/ L135P and Reep6þ/ L135Pmice. After
completion of the scotopic ERG, mice were light-adapted to a 30
ccd/m2 white background for 2 cmin, and photopic ERGs record-
ings were obtained at flash intensities of 0, 10, and 25 cdB. The
LKC UTAS Visual Diagnostic System and EMWIN software (LKC
Technologies) was utilized to digitize and store the recordings.
ERG data was analyzed and plotted using GraphPad Prism5 soft-
ware (GraphPad Software).Spectral-Domain Optical Coherence Tomography
Total retinal thickness and thickness of the outer nuclear layer
(ONL) was assessed and measured using an ultrahigh resolution
Spectral Domain Ophthalmic Imaging System (Envisu R2200
SDOIS, Leica Microsystems). Retinal imaging of each eye from
Reep6 WT, Reep6þ/L135P, and Reep6L135P/L135P mice was performed
on mice anesthetized by intraperitoneal injection of a ketamine/
xylazine cocktail (ketamine, 100 mg/kg; xylazine, 10 mg/kg) after
dilating eyes with one drop 1% cyclopentolate hydrochloridember 1, 2016
ophthalmic solution (Baush & Lomb) followed by one drop of
2.5% phenylephrine hydrochloride ophthalmic solution (Falcon
Pharmaceuticals). Eyes were lubricated using Systane Ultra lubri-
cant drops (Alcon) before dilation and GenTeal Severe lubricant
gel (Alcon) after dilation. The mice were then placed in the cylin-
drical mouse cassette on the rodent alignment stage (RAS) in front
of the optical scanningmouse retina bore. Pupils were centered us-
ing the X-, Y-, and Z-translators, and each eye was imaged along
the entire axial length. To minimize the anesthesia time, all of
the preparations were done in advance. The imaging of both
eyes was completed within 4–5 min per mouse. Image acquisition,
assessment, and processing were done using the InVivoVue 2.2
Image Acquisition Software (Leica Microsystems).Histology and Transmission Electron Microscopy
Mice were euthanized with isoflurane followed by cervical disloca-
tion. Eyes were enucleated from mutant and control animals and
fixed overnight at 4C in fresh Davidson’s fixative.18 Fixed eyes
were processed through ethanol dehydration series (50%, 70%,
95%, 100%) for 1 hr each. Eyes were then paraffin embedded
for microtome sectioning. Serial paraffin sections (7 mm) were
obtained and H&E stained according a standard protocol. All
H&E-stained slides were visualized using light microscopy (Zeiss
Apotome) and photoreceptor nuclei were counted and quantified.
For transmission electron microscopy (TEM), fresh eye cups were
dissected from mice and fixed in EM fixative comprising 2.5%
glutaraldehyde, 1% PFA, and 0.1 M PBS (pH 7.3) overnight at
4C. Samples were post fixed in 1% osmium tetroxide and
dehydrated in a series of graded alcohols. Conjunctiva samples
were infiltrated with acetone and PolyBed 812 plastic resin and
embedded in plastic molds with 100% plastic resin. Sections of 1
micron (thick) and 80–90 nm (thin) were cut (Leica Ultracut R
ultramicrotome). Thick sections were stained with Touludine
Blue stain and thin sections were placed on copper mesh grid
stained with uranyl acetate and lead citrate. Zeiss EM902 was
used for visualizing the sections and imaging was performed on
AMT V602 digital camera.Results
Biallelic REEP6 Mutations Identified in Individuals
with Retinitis Pigmentosa
Using a combination of WES, WGS, and direct Sanger
sequencing, mutations in REEP6 were identified in seven
individuals with RP from five unrelated families.
A simplex RP individual (A-II:1), an Asian male from a
non-consanguineous family, and individual B-II:8, one of
three male siblings with RP born to consanguineous par-
ents of African descent, were selected for WES after nega-
tive screening by targeted capture sequencing of 226 and
176 genes known to harbor pathogenic mutations associ-
ated with inherited retinal disease, respectively. WES data
revealed 463 rare single-nucleotide variants (SNVs) for
individuals A-II:1 and 549 rare SNVs were identified for
individual B-II:8. For individual A-II:1, based on the
presumed recessive inheritance, genes with two or more
variants were prioritized and variants were excluded in
genes if at least one of the variants was predicted to be
benign or neutral by at least 4/5 of the algorithms used,The American Jouor if homozygous loss-of-function (LOF) genotype was
observed in the ExAC database (Table S1). Based on these
filtering criteria, we eliminated six out of eight genes leav-
ing biallelic variants in BRCA2 (MIM: 600185) and REEP6.
BRCA2 is a well-characterized tumor suppressor gene, mu-
tations in which are associated with cancers of the breast,
brain, pancreas, and prostate; thus, biallelic variants iden-
tified in BRCA2were deemed unlikely to be associated with
RP based on biological plausibility. The biallelic variants in
REEP6 remained the only candidate RP-associated variants.
Thirty-six homozygous variants were identified in indivi-
dual B-II:8 (Table S2). Interrogation of the variant call
quality, MAF in the ExAC database, predicted protein
impact, prior disease association, expression pattern, and
predicted or known function of the proteins led to the pri-
oritization of REEP6 as the most compelling candidate
variant.
Individual A-II:1 (EG76) harbored compound heterozy-
gous variants in REEP6: a missense mutation (GRCh37
[hg19] chr19:g.1496339T>C, GenBank: NM_138393.1;
c.404T>C [p.Leu135Pro]) and a single-nucleotide deletion
also in exon 4 (GRCh37 [hg19] chr19:g.1496383del, Gen-
Bank: NM_138393.1; c.448del [p.Ala150Pfs*2]) (Figures 1A
and 1B). Both variants are absent in any publicly available
databases (Table 1). The close proximity of the two vari-
ants, with a distance of only 44 bp, allowed interrogation
of the 100 bp paired end reads using the Integrative Geno-
mics Viewer19,20 and confirmation of the biallelic state
(Figure 1C).
A homozygous variant in REEP6 (GRCh37 [hg19]
chr19:g.1496629dup) was identified in individual B-II:8
(GC18419; Figures 1A and 1B). This variant is absent from
any databases (Table 1). Interestingly, although this is
intronic in the canonical REEP6 transcript (REEP6.2, Gen-
Bank: NM_138393.2, c.517þ177dup), it is located within
exon 5 of a retinal-specific REEP6 transcript (REEP6.1, Gen-
Bank: NM_001329556.1). Importantly, Reep6.1 appears to
be the major isoform expressed in the mouse retina.21
This variant is predicted to cause a frameshift leading to
12 novel amino acid residues followed by a premature
stop codon (REEP6.1, c.557dup [p.Val187Glyfs*13]) that
affects only the retinal-specific isoform REEP6.1.
Subsequent interrogation of WGS data from 599 unre-
lated individuals with inherited retinal disease revealed
a large homozygous genomic rearrangement encom-
passing the first exon of REEP6 in an RP-affected indivi-
dual of Turkish descent (individual C-II:1, GC20453) in
the absence of plausible causative mutations in any
gene known to be associated with retinal disease or
other candidate genes. Examination of split reads
across the rearrangement and confirmation by direct
Sanger sequencing across the breakpoints revealed a
homozygous deletion of 6,886 bp (GRCh37 [hg19]
chr19:g.1485434_1492319) with an insertion of an
inverted 158 bp segment from the middle of the deleted
region (GRCh37 [hg19] chr19:g.1489259_1489416) com-
prising part of an AluY repeat sequence (Figures 1Arnal of Human Genetics 99, 1305–1315, December 1, 2016 1309
Table 1. Summary of Affected Individual Genotypes and Demographics
ID REEP6 Variant Protein Consequence
Ancestry, Age
of Diagnosis, Sex
Frequency of Variant in
Control (ExAC) Database Prediction
A-II:1 c.404T>C, c.448del p.Leu135Pro, p.Ala150Profs*2 Asian, 5, M 0/119,812 damaging no
product
B-II:8 REEP6.1: c.557dup, c.557dupC;
REEP6.2: c.517þ177dup,
c.517þ177dup
REEP6.1: p.Val187Glyfs*13,
p.Val187Glyfs*13
Sudanese, 20, M 0/16,014 PTC in REEP6.1
C-II:1 c.5835_115þ936delins,
AC027307.5:79083_79240inv,
c.5835_115þ936delins,
AC027307.5:79083_79240inv
p.0?, p.0? Turkish, 10, M NA no product
D-II:5 c.383C>T, c.383C>T p.Pro128Leu, p.Pro128Leu Iranian, early
childhood, M
0/119,724 damaging
E-II:1 c.279_280del, c.279_280del REEP6.1: p.Leu94Valfs*86,
p.Leu94Valfs*86; REEP6.2:
p.Leu94Valfs*320,
p.Leu94Valfs*320
Asian Indian, 14, M 1/120,294 PTC, out-of-frame
extension
Ages are indicated in years. Abbreviations are as follows: M, male; F, female; NA, not available; PTC, premature termination codon.and 1B, Table 1) (GRCh37 [hg19] chr19:g.1485434_
1492319delinsAC027307.5:79083_79240inv) spanning
exons 1–8 of PCSK4 (MIM: 600487, GenBank: NM_
017573.3; c.1974_1069–1308delinsAC027307.5:79083_
79240) on the reverse strand and REEP6 exon 1 on
the forward strand (GenBank: NM_138393.1, c.5835_
115þ936delinsAC027307.5:79083_79240inv). This previ-
ously unreported rearrangement was not present in any
other individual in our in-house dataset of 4,500 WGS
samples. Loss of the first coding exon and upstream
sequence is predicted to abolish REEP6 and PCSK4 expres-
sion. There were no extra-ocular findings attributable to
loss of PCSK4.
Additional direct Sanger sequencing of all the coding
exons of REEP6 in a panel of 400 RP-affected individuals
with unknown genetic etiology revealed two additional
individuals (D-II:5, GC2027, and E-II:1, GC15672), of Ira-
nian and Indian descent, respectively, with homozygous
variants in REEP6. A homozygous missense mutation in
exon 4 (GRCh37 [hg19] chr19:g.1496318C>T, GenBank:
NM_138393.1, c.383C>T [p.Pro128Leu]) was identified
in individual D-II:5 (Figures 1A and 1B). This unique
variant affects a conserved residue and is predicted
to be pathogenic (SIFT) and possibly damaging (Poly-
Phen-2) by in silico analysis. A two-nucleotide deletion
in exon 3 (GRCh37 [hg19] chr19:g.1495537_1495538del,
GenBank: NM_138393.1, c.279_280del) leading to frame-
shift that extends beyond the stop codon in the canoni-
cal transcript (p.Leu94Valfs*320, REEP6.2) and premature
termination in the alternatively spliced exon of the
retinal transcript (p.Leu94Valfs*86, REEP6.1) was identi-
fied in individual E-II:1 (Figures 1A and 1B). This variant
was found in a single allele in the ExAC dataset (1/
120,294). Direct Sanger sequencing of these suspected
disease-associated mutations in the probands and all
available affected and unaffected family members con-
firmed segregation with RP.1310 The American Journal of Human Genetics 99, 1305–1315, DeceClinical Phenotype
One affected individual from of each of the five families
was available for clinical investigation; the clinical find-
ings are summarized in Table S3. All affected individuals
presented with initial symptoms of nyctalopia with a
gradual decline in vision characterized by reduced periph-
eral visual fields and later reduced visual acuity. Onset
varied from early childhood to 20 years of age. At last re-
view with a mean age of 35.8 years (range 20 to 54), visual
acuity ranged from 0.18 log MAR (Snellen 20/30) to
1.3 log MAR (Snellen 20/400). All affected individuals
had significantly constricted visual fields ranging from
less than 10 degrees to 30 degrees. Affected individuals
from families B, C, D, and E had posterior subcapsular cat-
aracts (PSCs) that had required cataract surgery in two
cases. Fundus examination revealed attenuated retinal
vessels and mid-peripheral hypopigmentary mottling
due to atrophy of the retinal pigment epithelium (RPE).
Intra-retinal pigmentary migration (‘‘bone spicules’’) was
documented in all but individual D-II:5 (Figure 2). OCT
imaging of the macula performed in all affected individ-
uals demonstrated outer retinal atrophy with centrally
preserved inner segment ellipsoid (ISe) bands. In addition,
individuals B-II:8 and D-II:5 had cystoid macular edema
responsive to topical carbonic anhydrase inhibitors.
Fundus autofluorescence (FAF) imaging revealed para-
foveal rings of increased autofluorescence with wide-
spread mid-peripheral loss of autofluorescence, which
had nummular features in three affected individuals
(Figure 2). Electrophysiology testing available in individ-
uals A-II:1, E-II:4, and D-II:5 demonstrated a severe gener-
alized retinal dystrophy with severely reduced or unde-
tectable responses in individuals A-II:1 and D-II:5 in
their twenties and a severe rod-cone dystrophy in individ-
ual E-II:4 at age 15 years. The clinical presentations,
course, and electrophysiological findings were consistent
with a clinical diagnosis of RP.mber 1, 2016
Figure 2. Clinical Findings for Individuals
with Autosomal-Recessive RP Harboring
REEP6 Variants
(A) Retinal imaging of the left eye of indi-
vidual II:1 at age 18 years from family A.
(B) Retinal imaging of the left eye of indi-
vidual II:8 at age 32 years from family B.
(C) Right eye retinal imaging of individual
II:5 at age 54 years from family D.
(D) Retinal imaging of the right eye of indi-
vidual II:4 from family E.
Fundus imaging, fundus autofluorescence
imaging, andoptical coherence tomography
(OCT) scan reveal typical retinitis pigmen-
tosa features inall affected individuals.Color
fundus photographs demonstrate severely
constricted retinal arterioles, mid-peripheral
retinal pigment epithelium (RPE) atrophy,
retinal atrophy within and extending out-
ward of vascular arcades, and intraretinal
pigmented spicules. Fundus autofluores-
cence imaging demonstrates a hyperauto-
fluorescent ring around fovea and areas of
circumscribedhypoautofluorescencewithin
and extending outward of vascular arcades.
OCT demonstrates atrophy of the outer
retina with small bands of retained photore-
ceptors (arrows) that correspond to the areas
within the para-foveal rings.Expression of REEP6.1 in Human Photoreceptors
One of the variants identified is located in the intron
(IVS4) of the canonical transcript but lies within an
alternatively spliced exon in a retina-specific isoform
(REEP6.1). This retinal isoform was identified in mice
(Reep6.1) and includes an additional exon (exon 5) coding
for 27 amino acid residues, expressed specifically in rod
photoreceptors under the control of the transcription fac-
tor NRL.21 RNA-seq data from human retinal tissue
confirms the presence of the REEP6.1 isoform in human
retina22 (annotated as GenBank: NM_001329556.1). To
examine the expression of both REEP6 isoforms in human
tissue, iPSC-derived 3D organoid optic cups were uti-
lized.16 RT-PCR analysis over the time course of optic
cup differentiation showed that the expression of the
REEP6.1 isoform correlated with the time course of photo-
receptor development (Figure 3A).16 REEP6.1 was the
predominant isoform (75%) present in mature optic
cups, which is consistent with disruption of this isoform
causing RP. REEP6 immunoreactivity was confined to the
cell body and inner segment (IS) of developing human
rod photoreceptor cells (Figure 3B) and was not detected
in the rod outer segment (OS) (Figure 3B) or cone photore-
ceptors (Figure 3C).Functional and Structural Consequences of REEP6
Variants
REEP6 is a member of the REEP/Yop1 family of proteins
based on protein domain homology. REEPs are proposed
to influence the structure of the endoplasmic reticulum
(ER), but the function of REEP6 is yet to be eluci-
dated. REEP6 is an ER-localized protein;23 however, theThe American Joulocalization of the retinal isoform, REEP6.1, is not known.
To test this, a WT REEP6.1 (GenBank: NM_001329556.1)
expression construct was transiently transfected in SK-N-
SH neuroblastoma cells. Similar to the canonical iso-
form, REEP6.1 protein also localized mainly to the ER
(Figure 3D). Furthermore, localization of the p.Pro128Leu,
p.Leu135Pro, and p.Val187Glyfs*13 variants was also
predominantly ER (Figure S1); however, inhibition of
proteasome function revealed that p.Pro128Leu and
p.Leu135Pro could form intracellular inclusions, suggest-
ing a level of protein instability (Figure S1). This was
confirmed by testing the steady-state expression levels,
which showed that all the variants had decreased protein
levels in SK-N-SH cells than the WT REEP6.1 (Figure S1)
and the p.Val187Glyfs*13 showed a significantly short-
ened half-life (Figure S1). Furthermore, this frameshift
variant is predicted to undergo nonsense-mediated decay
(NMD), suggesting that the level of endogenous mRNA
could also be affected. Together, these data suggest that
REEP6.1 is an ER protein and that the identified variants
affect protein stability.The REEP6 p.Leu135Pro Missense Variant Is
Pathogenic
To examine the function of the p.Leu135Pro variant
identified in this study in vivo, a mouse knock-in model
of Reep6 p.Leu135Pro was generated using CRISPR-Cas9
technology. The Reep6L135P/L135P homozygous knock-in
mice were viable and fertile, exhibiting no obvious mor-
phological abnormalities upon gross examination. Immu-
nostaining revealed no change in Reep6 localization in
the Reep6L135P/L135P homozygous knock-in mouse retinarnal of Human Genetics 99, 1305–1315, December 1, 2016 1311
Figure 3. Expression and Localization of REEP6 in Human iPSC
Photoreceptors
(A) Reverse-transcription PCR analysis of REEP6.1 and 6.2 isoforms
in control adult fibroblasts (fibs) and control BJ optic cups during
different weeks (wk) of photoreceptor differentiation. GAPDH
used a loading control.
(B) Maturing rhodopsin-positive rod cells (green) co-express
REEP6 (red) in the IS and cell body (CB). At a later stage of devel-
opment, mature rods develop rhodopsin-laden outer segments
(green) in which REEP6 staining (red) is not detectable despite
its continued expression in the IS and CB.
(C) REEP6 (red) is not detectable in maturing cones, expressing
cone arrestin (green). Mature cones (green) remain REEP6 (red)
negative at this stage of development. Nuclei are counter-stained
with DAPI (blue).
(D) ER localization of REEP6.1. REEP6.1 WT (green) was expressed
in SK-N-SH cells, stained with anti-REEP6, and counterstained
with anti-KDEL (red).
Scale bars represent 10 mm.
1312 The American Journal of Human Genetics 99, 1305–1315, Dececompared to the control retina. Additionally, western blot
revealed that Reep6 protein levels were similar in Reep6WT
and KI retinae (Figure S2). Histological analysis of the
Reep6L135P/L135P retina revealed subtle changes in the over-
all retinal thickness and retinal morphology compared to
WT or Reep6þ/L135P at 4 months (Figure 4A); however, by
6 months, Reep6L135P/L135P mutant mice exhibited signifi-
cant thinning of the ONL and reduced rows of nuclei
when compared to Reep6þ/L135P littermate controls
(Figure 4B). Furthermore, retinal live imaging by SD-OCT
in 2-, 4-, and 6-month-old mice was consistent with the
changes observed histologically (Figure S3). To examine
the defects at the ultrastructural level, transmission EM
(TEM) on P20 and 6-month-old Reep6L135P/L135P mutant
and Reep6þ/L135P control mice was performed (Figure 4B).
Although the overall retinal layer organization appeared
normal in the Reep6L135P/L135P mutant retina at P20, severe
alterations in the IS and OS in Reep6L135P/L135P mutant
retina were evident compared to Reep6þ/L135P control
retina by 6 months of age (Figure 4). Electrophysiology
was performed on Reep6L135P/L135P mice and Reep6þ/L135P
controls at 4 and 6 months. Photopic ERG recordings of
4-month-old Reep6L135P/L135Pmutant mice showed normal
cone activity compared to Reep6þ/L135P control mice;
however, the full-field scotopic ERGs showed both a- and
b-wave reduction in Reep6L135P/L135P mice compared to
the heterozygous littermate controls (Figure 4C) consistent
with rod photoreceptor dysfunction, and this was reduced
further at 6 months (data not shown). Collectively, these
data demonstrate that the p.Leu135Pro missense variant
is indeed pathogenic and mutation in Reep6 causes pro-
gressive loss of rod photoreceptor function and survival
in mice.Discussion
We report biallelic mutations of REEP6 in seven affected
individuals from five families with retinal dystrophy. Mu-
tations were not restricted to specific exons or domains
of REEP6 and include a 7 kb genomic rearrangement
comprising deletion of the first exon and 50 UTR that
would abolish gene transcription, three frameshift muta-
tions, two missense mutations, and a frameshift mutation
in the rod photoreceptor-specific exon of the retinal iso-
form that is not expected to affect the canonical transcript.
Mutations in REEP6 have not been implicated in any
human disease previously, and these data show that muta-
tions in REEP6 can cause inherited retinal dystrophy.
REEP6 is a member of the REEP family of proteins that
are related to the Deleted in Polyposis 1 (DP1)/Yop1p
family identified in yeast. Six human REEP transmembrane
proteins have been annotated that were initially suggested
to have a role in enhancing the expression of cell surface
olfactory receptors, G protein coupled receptors (GPCR),
and taste receptors.24 REEP6 can interact with select vesicle
cargo proteins, such as a2C adrenergic receptor proteins,mber 1, 2016
Figure 4. Reep6L135P/L135P Mutant Mice Exhibit Photoreceptor Degeneration
(A) Histological analysis of retinal sections from Reep6þ/L135P (left) and Reep6L135P/L135P (right) mice was performed at 4 months and
6 months of age. Reep6þ/L135P retina shows normal layered organization compared to the Reep6L135P/L135P retina that shows moderate
thinning of the outer nuclear layer (ONL) at 4 months and marked thinning at 6 months of age. ‘‘INL’’ indicates inner nuclear layer.
Scale bars represent 40 mm.
(B) TEM images of P20 and 6-month-old retina from Reep6þ/L135P control retina and Reep6L135P/L135P mutant retina shows thinning of
ONL, outer segment (OS), and inner segment (IS) at 6 months of age indicative of progressive retinal degeneration. Scale bars represent
2 mm (top) and 10 mm (bottom).
(C) Quantitative evaluation of scotopic a-wave and b-wave and photopic b-wave amplitude data for 4-month-old Reep6þ/L135P control
retina and Reep6L135P/L135P mutant mice.
NS indicates not significant, **significant at p < 0.01, ***significant at p < 0.001.and modulate their intracellular processing by affecting
the ER cargo capacity to enhance their expression at the
cell surface.23 Therefore, REEP6 could play a similar role
in enhancing photoreceptor GPCR traffic and this could
be probed in future studies using the knock-in mouse
model.
REEPs and Yop1p are ER-resident proteins that act
as membrane-shaping adaptor proteins to regulate ER
membrane structure.23,25–28 Mutations in REEP1 (MIM:
609139) and REEP2 (MIM: 609347) cause autosomal-domi-
nant hereditary spastic paraplegia (MIM: 610250) and
distal hereditary motor neuropathy (MIM: 614751).29–31
Recent studies have shown that REEP1 is important in
neurite development and establishing the structure of
the peripheral ER32 and in facilitating ER-mitochondria
interactions.33 Therefore, it will be relevant to study how
loss of REEP6 function affects the photoreceptor ER and
mitochondria. The photoreceptor ER is highly specializedThe American Jouto produce many of the proteins and lipids that constitute
the light-sensitive OS. Furthermore, photoreceptor mito-
chondria are concentrated at the tip of the IS near the
base of the OS; it is possible that REEP6 has a role in special-
izing the photoreceptor ER and/or mitochondria.
RNA-seq in mice led to the discovery of an isoform of
Reep6, Reep6.1, expressed specifically in rod photorecep-
tors.21 In this study we show that REEP6.1 is the predomi-
nant isoform in developing human photoreceptors and,
indeed, REEP6 expression appears to be limited to rod pho-
toreceptors in human 3D optic cups. The rod-specific
expression pattern is consistent with the rod:cone dystro-
phy observed in affected individuals and the p.Leu135Pro
homozygous knock-in mice. We identified a homozygous
single-nucleotide duplication within intron 4 of the
canonical transcript of REEP6 that leads to a frameshift
and premature termination of the REEP6.1 transcript
(c.557dupC [p.Val187Glyfs*13]) in an affected individual.rnal of Human Genetics 99, 1305–1315, December 1, 2016 1313
This finding further suggests that REEP6.1 is an important
transcript within rod photoreceptors and that disruption
of its function alone can lead to retinal dystrophy.
The C-terminal regions of the REEP family are divergent,
suggesting a specific role for this domain of the protein.
Furthermore, mutations in REEP1 often result in loss of
the C-terminal region and loss of the 14-3-3 binding
domain.29,33 This domain may be important for intracel-
lular signaling and such mutations in REEP1 may disrupt
neuronal signaling in this way without affecting the
ER.23,34 REEP6 lacks the 14-3-3 binding domain found in
REEP1-4, and the REEP6.1 isoform has an additional C-ter-
minal helix. This domain could mediate specific interac-
tions in rod photoreceptors, potentially binding specific
interacting proteins or mediating interactions between
the ER and mitochondria.
Collectively, in addition to identifying variants in REEP6
in individuals with RP, these findings highlight the utility
of CRISPR-Cas9 gene editing to model human diseases.
The p.Leu135Pro homozygous knock-in mice effectively
replicate the RP phenotype and confirm that this variant
is dysfunctional and that REEP6 is required to maintain
retinal function and survival. Future studies will examine
the role of REEP6 in retinal biology and understanding
its involvement inmaintenance of photoreceptor function
and survival.Accession Numbers
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